<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BCD05341-5D48-43F1-A505-C169496883A1"><gtr:id>BCD05341-5D48-43F1-A505-C169496883A1</gtr:id><gtr:name>University of Hong Kong</gtr:name><gtr:address><gtr:line1>Pok Fu Lam Road</gtr:line1><gtr:line4>Hong Kong</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Hong Kong</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9914949B-22C3-4FC5-9245-BFBC631252D9"><gtr:id>9914949B-22C3-4FC5-9245-BFBC631252D9</gtr:id><gtr:name>University of Hawaii</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Clinical Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C932CFE-AAE2-4A8F-A53F-1C7EAC961997"><gtr:id>9C932CFE-AAE2-4A8F-A53F-1C7EAC961997</gtr:id><gtr:name>Harvard University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BCD05341-5D48-43F1-A505-C169496883A1"><gtr:id>BCD05341-5D48-43F1-A505-C169496883A1</gtr:id><gtr:name>University of Hong Kong</gtr:name><gtr:address><gtr:line1>Pok Fu Lam Road</gtr:line1><gtr:line4>Hong Kong</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Hong Kong</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9914949B-22C3-4FC5-9245-BFBC631252D9"><gtr:id>9914949B-22C3-4FC5-9245-BFBC631252D9</gtr:id><gtr:name>University of Hawaii</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4078502E-4611-49D3-8E8A-05B4F529EA45"><gtr:id>4078502E-4611-49D3-8E8A-05B4F529EA45</gtr:id><gtr:firstName>Hanh</gtr:firstName><gtr:surname>Doan Thi Hong</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B6B9BBF4-BE38-40E2-AE0B-AAEE2E5B04EA"><gtr:id>B6B9BBF4-BE38-40E2-AE0B-AAEE2E5B04EA</gtr:id><gtr:firstName>Marcel</gtr:firstName><gtr:surname>Wolbers</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/87E8E0FF-93EF-4131-A389-4687F8D466CB"><gtr:id>87E8E0FF-93EF-4131-A389-4687F8D466CB</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Horby</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/61A12C6D-128A-4EB3-A211-4193E6A2CEA8"><gtr:id>61A12C6D-128A-4EB3-A211-4193E6A2CEA8</gtr:id><gtr:firstName>Mattias</gtr:firstName><gtr:surname>Larsson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D1C5947D-8FD1-4F79-A0C9-C0432A8D2B38"><gtr:id>D1C5947D-8FD1-4F79-A0C9-C0432A8D2B38</gtr:id><gtr:firstName>Alastair</gtr:firstName><gtr:otherNames>McIntosh</gtr:otherNames><gtr:surname>Gray</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/85D780C7-1091-4550-A5C1-208E49F7644B"><gtr:id>85D780C7-1091-4550-A5C1-208E49F7644B</gtr:id><gtr:firstName>Chi H</gtr:firstName><gtr:surname>Nguyen</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/9024380E-ED08-4727-8AAD-E2864A7D31CF"><gtr:id>9024380E-ED08-4727-8AAD-E2864A7D31CF</gtr:id><gtr:firstName>Cuong</gtr:firstName><gtr:otherNames>Duy</gtr:otherNames><gtr:surname>Do</gtr:surname><gtr:orcidId>0000-0001-9940-2306</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/08A7725D-D312-4AA2-BB7F-8287EF8A1589"><gtr:id>08A7725D-D312-4AA2-BB7F-8287EF8A1589</gtr:id><gtr:firstName>Kinh</gtr:firstName><gtr:surname>Nguyen Van</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0180270E-4D27-4B1D-838E-7C64B46D9D1E"><gtr:id>0180270E-4D27-4B1D-838E-7C64B46D9D1E</gtr:id><gtr:firstName>Thuy</gtr:firstName><gtr:surname>Le</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D58D9098-CD92-436D-909F-5908069FC028"><gtr:id>D58D9098-CD92-436D-909F-5908069FC028</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Farrar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100682"><gtr:id>50AA99BD-6E93-4CAB-A2E7-F688251E0CAD</gtr:id><gtr:title>A Randomised, Open-Label, Comparative Study of Itraconazole vs. Amphotericin B for the Induction Therapy of Penicilliosi</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100682</gtr:grantReference><gtr:abstractText>Penicilliosis is one of the most common and life-threatening infections in people infected with Human Immunodeficiency Virus (HIV) in Asia. Despite the fast growing numbers of people infected with HIV in Asia where over one half of the world?s population lives, there has not been any clinical trials to evaluate the treatment of penicilliosis. The current international guideline recommends treatment with amphotericin B for 2 weeks followed by itraconazole for 10 weeks. This guideline is based on one observational study without a comparator group and is generally considered weak evidence in medicine. Further, amphotericin B is either unavailable or available in only selected major tertiary care centres in Asia, can only be given through a vein daily over 6 hours of infusion, has many side effects, and a 2 week treatment in Viet Nam for example would cost an average patient approximately 5 times his monthly salary . Itraconazole, on the other hand, appears to be a good alternative drug that is widely available in local pharmacies in the provinces and district clinics, can be given by mouth, is generally well tolerated, and costs a fraction of the price of amphotericin B. Available data from Viet Nam, Thailand, Hong Kong and India suggest that itraconazole may have similar treatment efficacy compared to amphotericin B. Therefore we will conduct a clinical trial comparing the relative effectiveness of itraconazole versus amphotericin in the treatment of penicilliosis. A total of 440 adults who are diagnosed with penicilliosis will be invited to participate in the study and will be randomly assigned to either itraconazole or amphotericin B during the first 2 week of therapy. Survival rates will be compared in the 2 treatment arms at the end of 2 weeks and in 6 months. This will be the landmark study for treatment of penicilliosis. The results will either change or support the current national and international guidelines for treatment of penicilliosis. If the investigators are correct, that itraconazole is proven to be at least as effective as amphotericin B, but is much cheaper, better tolerated, and easier to administer, then itraconazole represents a better treatment choice for the patients with penicilliosis while saving significant costs for the patients and the health care system. If the investigators are correct, then itraconazole can be given immediately for patients in the local provincial and district clinics, ensuring earlier treatment and better outcomes for patients.</gtr:abstractText><gtr:technicalSummary>Penicilliosis is emerging as one of the three most common HIV-associated opportunistic infections in Asia. Despite the rapid growing HIV epidemics in a region that houses one half of the worlds population, there has not been a single randomised controlled trial to evaluate the treatment of penicilliosis. The current recommendation of amphotericin B for 2 weeks followed by itraconazole for 10 weeks is based on one non-comparative study [1]. Amphotericin B has extremely limited availability, has significant side effects, needs to adminstered through a vein daily over 6 hours of infusion, and is prohibitively expensive in most areas of Asia. Itraconazole, on the other hand, is widely available in local pharmacies throughout Asia, can be given orally at a fraction of the price. Further, data from available case series suggest that itraconazole and amphotericin B have similar efficacies. We therefore propose to conduct a randomised, open-label, non-inferiority trial of the efficacy of itraconazole versus amphotericin B for penicilliosis. 440 adults from in and outpatient settings with culture-confirmed penicilliosis will be recruited, randomly allocated to either itraconazole or amphotericin B treatment, monitored daily in-hospital for 2 weeks, and at monthly intervals for a total of 6 months. Primary outcome is mortality at 2 weeks. Secondary outcomes include 6-month survival, clinical response, relapse, drug tolerability, and economic costs. Correlates of interests include admission prognostic factors, time-to-culture-sterilization, fungicidal activities, pharmacokinetic parameters, and serologic titres. These results will be available within five years and will either change or support current treatment guidelines for penicilliosis.</gtr:technicalSummary><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1540178</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hong Kong</gtr:collaboratingOrganisation><gtr:country>Hong Kong, Special Administrative Region of China</gtr:country><gtr:description>Partnership with the University of Hong Kong to develop serological diagnostics for talaromycosis</gtr:description><gtr:id>121889C4-CAD1-4887-9401-8762DE76B89B</gtr:id><gtr:impact>This collaboration has resulted in 2 abstracts presented at the Vietnam National Infectious Disease Conference, 2016 and the 24th Conference on Retroviruses and Opportunistic Infection in Seattle, 2017, as follows:
1. Thu NTM, Hien HTA, Tung NLN, Day J, Vinh Chau NV, Thwaites G, Chan FWC, Yuen KY, and Le T. Rapid serodiagnosis of Talaromyces marneffei infection. 5th Vietnam National Conference in Infectious Diseases and HIV. Sep 17-18, 2016. Hanoi, Vietnam. 
2. Thu NTM, Chan JFW, Hien HTA, Tung NLN, Thanh NT, Day JN, Vinh Chau NV, Thwaites G, Woo P, Yuen KY, Le T. Clinical Performance of the Mp1p Immunoassay for Rapid Diagnosis of Talaromyces marneffei Infection. Conference of Retroviruses and Opportunistic Infections. Feb 13-16, 2017. Seattle, WA, USA.</gtr:impact><gtr:outcomeId>58c6c11db0fa80.24969229-1</gtr:outcomeId><gtr:partnerContribution>Researcher at the University of Hong Kong (Prof. KY Yuen's group) has developed a monoclonal antibody-based ELISA that enable rapid diagnosis of talaromycosis. They will be providing antibodies for the validation of the assay to be performed in Vietnam, and will continue to collaborate on future grant applications to improve talaromycosis diagnostics.</gtr:partnerContribution><gtr:piContribution>We have developed a sera bank of samples from patients with culture-confirmed talaromycosis and control patients without the disease that enable external validation and optimization of the antigen detecting Mp1p ELISA developed by the research group in Hong Kong</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Havard Medical School AIDS Inititive in Vietnam (HAIVN)</gtr:description><gtr:id>05451B93-9AB4-410E-9D93-1096F0D3C64B</gtr:id><gtr:impact>Ongoing</gtr:impact><gtr:outcomeId>kkdYGNj3QiG-1</gtr:outcomeId><gtr:partnerContribution>HAIVN runs the clinical trials and provides clinical samples and data for us to study HIV drug resistance development.</gtr:partnerContribution><gtr:piContribution>Collaborate in a randomized controlled trial to evaluate viral load monitoring to improve HIV treatment outcome in Vietnam</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The James Martin Stem Cell Facility</gtr:department><gtr:description>Partnership with the University of Oxford Health Economic Centre</gtr:description><gtr:id>C992151C-2BFE-4668-A98F-C7E68F0545C2</gtr:id><gtr:impact>An abstract submitted to a conference on Revolutions in the Economics of Health Systems in Boston July 2017</gtr:impact><gtr:outcomeId>58c6d346ebf619.76307130-1</gtr:outcomeId><gtr:partnerContribution>Data analysis is ongoing</gtr:partnerContribution><gtr:piContribution>This project has brought together a collaborative partnership with Prof. Alaistar Gray at the University of Oxford Health Economic Research Centre to conduct the cost and cost effective analyses of talaromycosis treatment</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Molecular and Clinical Pharmacology</gtr:department><gtr:description>Collaboration with Prof. William Hope to study the clinical phamacology of itraconazole and amphotericin B in treatment of penicilliosis</gtr:description><gtr:id>FE717EA3-89E5-4C82-9990-551D3ADC74C4</gtr:id><gtr:impact>This collaboration is leading to a program grant application we are writing.</gtr:impact><gtr:outcomeId>5461d730533f31.68341290-1</gtr:outcomeId><gtr:partnerContribution>Prof. William Hope's lab provided measurement of drug levels (in kind) and provided expertise in PK/PD modeling</gtr:partnerContribution><gtr:piContribution>We designed and collected samples for the PK/PD study to determine therapeutic drug level and dosing intervals for treatment of penicilliosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hawaii</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Hawaii Center for AIDS</gtr:department><gtr:description>Vietnam Hawaii AIDS Research Partnership</gtr:description><gtr:id>8D34001C-5178-4320-AF28-4798484BC76A</gtr:id><gtr:impact>ongoing</gtr:impact><gtr:outcomeId>tVTy8AUq3Rs-1</gtr:outcomeId><gtr:partnerContribution>Obtaining the funding and providing research laboratory expertise</gtr:partnerContribution><gtr:piContribution>Collaborate with The Hawaii Center for AIDS in a clinical trial evaluating hepatoxicity of raltegravir versus efavirenz in combination with tenofovir and emtricitabine for treatment of HIV in patients coinfected with hepatitis C. I run the clinical trial in Vietnam.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>The epidemiology, diagnosis and treatment of penicilliosis</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BD0F1F6F-9C0E-4279-A276-A90ACECC70A2</gtr:id><gtr:impact>I gave a talk by video conference to HIV doctors in Vietnam about penicilliosis epidemiology, diagnosis and treatment

This is part of continue education for health care professionals in Vietnam</gtr:impact><gtr:outcomeId>Dap9MKHYx85</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>International Pilot Award</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>University of Washington</gtr:fundingOrg><gtr:fundingRef>NIH P30 AI 027757</gtr:fundingRef><gtr:id>D66A062A-E0E7-49F8-91CF-019FFFD8E57D</gtr:id><gtr:outcomeId>PJTKUkqzN2X</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>This project led to membership to the World Health Organization Guideline Development Group on Management of Advanced HIV</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>A90FEB61-8342-4072-8B0D-76BDC5C55BAA</gtr:id><gtr:impact>The study provided the data on the mortality benefit of amphotericin B (compared to itraconazole) for treatment of talaromycosis. The study provided doctors in Vietnam with clinical trial evidence to use amphotericin B as initial treatment of talaromycosis in their clinical practice. The study team is meeting with Vietnam Ministry of Health later on this year to present the data and to advocate for improved procurement and access to amphotericin B therapy in Vietnam. The study will be cited in the 2017 updated WHO guidelines which will mention treatment options for talaromycosis.</gtr:impact><gtr:outcomeId>58c6b41ca86fa2.37323760</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>This study resulted in a largest prospectively collected data from more than 400 patients with culture-confirmed talaromycosis in the world to date. This rich dataset will allow multiple follow up evaluations of factors that impact patient outcomes as well as development of future models to predict outcomes in patients.</gtr:description><gtr:id>006FEBF4-22EA-4D07-A18A-FC66AD4211C0</gtr:id><gtr:impact>This dataset will be shared with the research communities once our policy on data sharing is finalized.</gtr:impact><gtr:outcomeId>58c6c50b9c3a58.27359452</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Talaromycosis patient database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>This grant allows our group to develop a new real-time PCR assay that is able to detect pencilliosis within 5-6 hours in ~70% patients presenting without skin lesions, in whom conventional blood culture takes on average 5-7 days to diagnose the disease.</gtr:description><gtr:id>4CF84F16-9895-4D58-BAC4-1E68E75BA8F9</gtr:id><gtr:impact>Not yet. We are submitting the paper and hope to continue to develop the assay for clinical use.</gtr:impact><gtr:outcomeId>56e129c5beef30.66446217</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Developement of a new real-time PCR assay for rapid diagnosis of penicilliosis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This project improves the capacity of the 5 hospitals in Vietnam to conduct clinical trials</gtr:description><gtr:id>E8592491-700E-43AE-ACE2-92A424B2D0B9</gtr:id><gtr:impact>The five hospitals participated in this study has improved their capacity to conduct high standard clinical research</gtr:impact><gtr:outcomeId>58c6c3e7dbef18.05400027</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Good Clinical Practice training and training in the conduct of clinical trials</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This project has enabled 3 microbiology laboratories in the provinces of Vietnam to improve the capacity to diagnose talaromycosis by microscopy and culture</gtr:description><gtr:id>6E7E360A-5614-448A-B34B-40BC0FF69BD6</gtr:id><gtr:impact>The provincial hospitals participated in the study are now able to make microbiology-confirmed talarmycosis. They were only making clinical diagnosis before participating in the study.</gtr:impact><gtr:outcomeId>58c6c357953c51.49800901</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>This project has enabled 3 microbiology laboratories in the provinces of Vietnam to improve the capacity to diagnose talaromycosis by microscopy and culture</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The study enables the validation and optimization of a novel antigen detecting ELISA developed by our collaborators from Hong Kong for rapid and accurate diagnosis of talaromycosis</gtr:description><gtr:id>C8CDE918-344B-455A-96F8-35637073D774</gtr:id><gtr:impact>This method has allowed reduction of time to diagnosis of talaromycosis to on average 4 days, enable early treatment and improves patient outcomes.</gtr:impact><gtr:outcomeId>58c6c2775abe51.20007424</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Optimization of a serological assay for rapid diagnosis of talaromycosis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>This funding has allowed us to develop a new simple assay to detect and quantify the fungal load in patient blood</gtr:description><gtr:id>5FAB0E3F-31B1-43F0-8D97-1C4080FB6B03</gtr:id><gtr:impact>We are planning to publish this assay and hope that it can be used to monitor treatment response.</gtr:impact><gtr:outcomeId>56e12aefaadc51.67470073</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Development of a simple culture assay to quantify Penicillium marneffei in patient blood</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7546335C-E460-40A4-A5B1-59A0AC701E8E</gtr:id><gtr:title>Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c4724e2a5c7d3379ef01fabff0b7f22"><gtr:id>6c4724e2a5c7d3379ef01fabff0b7f22</gtr:id><gtr:otherNames>Beardsley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>56e13498b8e0e0.63017650</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FD8AE8D-DF6D-4F28-AEB1-C7D5D855E208</gtr:id><gtr:title>A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/234971086e1080b9c2e8a03abc822bb7"><gtr:id>234971086e1080b9c2e8a03abc822bb7</gtr:id><gtr:otherNames>Le T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5a9430026757f5.60891514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BECC1669-B3FE-4DB9-B30D-AFB54322AEC8</gtr:id><gtr:title>Invasive Non-typhoidal Salmonella Infections in Asia: Clinical Observations, Disease Outcome and Dominant Serovars from an Infectious Disease Hospital in Vietnam.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/60109520ccb49ee4c01bf26bf8c50c85"><gtr:id>60109520ccb49ee4c01bf26bf8c50c85</gtr:id><gtr:otherNames>Phu Huong Lan N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>58c6bb7ccb4046.75028958</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E44AF79C-3CC0-4A6C-8497-9F00107466F0</gtr:id><gtr:title>CPE debate still unresolved</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65beea7ceb2b9eee5ebc9704f3ead90e"><gtr:id>65beea7ceb2b9eee5ebc9704f3ead90e</gtr:id><gtr:otherNames>Justin Beardley, Thuy Le</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>5461d116c6d3a5.51145702</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>65C71B83-6F92-41A3-BE9F-066813B2202B</gtr:id><gtr:title>High prevalence of PI resistance in patients failing second-line ART in Vietnam.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2fdca735ca5352dcce9ebbfa672877"><gtr:id>1e2fdca735ca5352dcce9ebbfa672877</gtr:id><gtr:otherNames>Thao VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>56e13498580eb7.45314705</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>61EB679E-79FC-4992-9335-1B0B1B86FC66</gtr:id><gtr:title>HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2fdca735ca5352dcce9ebbfa672877"><gtr:id>1e2fdca735ca5352dcce9ebbfa672877</gtr:id><gtr:otherNames>Thao VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn><gtr:outcomeId>pm_13636_26_22473024</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF76AA1F-2943-4804-BE88-B934910ACC23</gtr:id><gtr:title>Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/234971086e1080b9c2e8a03abc822bb7"><gtr:id>234971086e1080b9c2e8a03abc822bb7</gtr:id><gtr:otherNames>Le T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>pm_13636_26_21427403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD4ADDCB-4DDE-464F-9B7A-718D6A1A8B23</gtr:id><gtr:title>The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19b4d0ec83979c16ac082361a17c4cff"><gtr:id>19b4d0ec83979c16ac082361a17c4cff</gtr:id><gtr:otherNames>Birger RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a942f42222863.06882372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>673E8C94-9CBC-4385-8C67-940ED300FE09</gtr:id><gtr:title>Clinical features of three patients with paradoxical immune reconstitution inflammatory syndrome associated withinfection.</gtr:title><gtr:parentPublicationTitle>Medical mycology case reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88bdf1f6946edbc42964027a9d202491"><gtr:id>88bdf1f6946edbc42964027a9d202491</gtr:id><gtr:otherNames>Thanh NT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2211-7539</gtr:issn><gtr:outcomeId>5a942d6c855cd5.60260428</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>498112F7-D2A1-4B82-9A34-BDADA1DC3B89</gtr:id><gtr:title>The decline of typhoid and the rise of non-typhoid salmonellae and fungal infections in a changing HIV landscape: bloodstream infection trends over 15 years in southern Vietnam.</gtr:title><gtr:parentPublicationTitle>Transactions of the Royal Society of Tropical Medicine and Hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/598c463aaba8eab10307c43bb1339d04"><gtr:id>598c463aaba8eab10307c43bb1339d04</gtr:id><gtr:otherNames>Nga TV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0035-9203</gtr:issn><gtr:outcomeId>pm_13636_26_22137537</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF7986DE-4534-46C8-95EB-A08DFD2C91ED</gtr:id><gtr:title>Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/234971086e1080b9c2e8a03abc822bb7"><gtr:id>234971086e1080b9c2e8a03abc822bb7</gtr:id><gtr:otherNames>Le T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>pm_13636_26_21412062</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>920A8F08-C138-4188-8D94-F9E38D994B38</gtr:id><gtr:title>Clinical characteristics and outcome of Penicillium marneffei infection among HIV-infected patients in northern Vietnam.</gtr:title><gtr:parentPublicationTitle>AIDS research and therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4639e8ef34a2b28d53c1c06374e34c12"><gtr:id>4639e8ef34a2b28d53c1c06374e34c12</gtr:id><gtr:otherNames>Larsson M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-6405</gtr:issn><gtr:outcomeId>pm_13636_26_22897817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0506276E-9C56-446E-AF2C-C286F322E48B</gtr:id><gtr:title>Itraconazole or Amphotericin B for Talaromycosis.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/234971086e1080b9c2e8a03abc822bb7"><gtr:id>234971086e1080b9c2e8a03abc822bb7</gtr:id><gtr:otherNames>Le T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5a942d30805bd2.97443257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9FFE9A4-AED6-4EFF-80D9-D57025E21593</gtr:id><gtr:title>Fungal infections in HIV/AIDS.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/11a2310a02e3c85380d065dd51c107cc"><gtr:id>11a2310a02e3c85380d065dd51c107cc</gtr:id><gtr:otherNames>Limper AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5a942dd87e6a14.80381674</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4E0EF39-7925-4AD6-8582-E693C6E09298</gtr:id><gtr:title>Looking for fungi in all the right places: screening for cryptococcal disease and other AIDS-related mycoses among patients with advanced HIV disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in HIV and AIDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03cd336163c85a32ca607e53846090b2"><gtr:id>03cd336163c85a32ca607e53846090b2</gtr:id><gtr:otherNames>Greene G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1746-630X</gtr:issn><gtr:outcomeId>58c6bb7c696ec4.55710154</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C09A83C-8160-4562-96F7-4C61561DF7B0</gtr:id><gtr:title>Environmental predictors and incubation period of AIDS-associated penicillium marneffei infection in Ho Chi Minh City, Vietnam.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55f031503605171dcbf9aacfdc64f6d3"><gtr:id>55f031503605171dcbf9aacfdc64f6d3</gtr:id><gtr:otherNames>Bulterys PL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn><gtr:outcomeId>KutjJBKAVqJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D85425F6-32C3-42D9-973C-C4CB8DCED366</gtr:id><gtr:title>Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam.</gtr:title><gtr:parentPublicationTitle>Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e2fdca735ca5352dcce9ebbfa672877"><gtr:id>1e2fdca735ca5352dcce9ebbfa672877</gtr:id><gtr:otherNames>Thao VP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0025-7974</gtr:issn><gtr:outcomeId>56e134988ba182.78235055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16870250-66AD-4C2A-8540-B651E08A143F</gtr:id><gtr:title>Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of Talaromyces marneffei MP1 gene in human plasma.</gtr:title><gtr:parentPublicationTitle>Mycoses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e60e4326d9be7959ec47f52aa175cd80"><gtr:id>e60e4326d9be7959ec47f52aa175cd80</gtr:id><gtr:otherNames>Hien HT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0933-7407</gtr:issn><gtr:outcomeId>58c6bb7ca28410.70107234</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B48CC82-0CE7-481C-9698-9AA306578E19</gtr:id><gtr:title>Diagnosing Rhodococcus equi infections in a setting where tuberculosis is highly endemic: a double challenge.</gtr:title><gtr:parentPublicationTitle>Journal of clinical microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/234971086e1080b9c2e8a03abc822bb7"><gtr:id>234971086e1080b9c2e8a03abc822bb7</gtr:id><gtr:otherNames>Le T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0095-1137</gtr:issn><gtr:outcomeId>56e11c46ea4fb6.92446830</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100682</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>